-
Akhtar J, Shukla D, 2009: Viral entry mechanisms: cellular andviral mediators of herpes simplex virus entry[J]. FEBS J, 276, 7228-7236. doi: 10.1111/j.1742-4658.2009.07402.x
-
Al-Dujaili L J, Clerkin P P, Clement C, McFerrin H E, Bhattacharjee P S, Varnell E D, Kaufman H E, Hill J M, 2011: Ocularherpes simplex virus: how are latency, reactivation, recurrentdisease and therapy interrelated?[J]. Future Microbiol, 6, 877-907. doi: 10.2217/fmb.11.73
-
Anderson J R, Behrens C, Binswanger I A, and al. e 2013, postingdate. HIV Web Study. http://depts.washington.edu/hivaids/oit/case7/discussion.html.
-
Arvin A M, 1996: Varicella-zoster virus[J]. Clin Microbiol Rev, 9, 361-381.
-
Arvin A M. 2007. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge; New York, pp. 1262-1273.
-
Azwa A, Barton S E, 2009: Aspects of herpes simplex virus: aclinical review[J]. J Fam Plann Reprod Health Care, 35, 237-242. doi: 10.1783/147118909789587376
-
Barron B A, Gee L, Hauck W W, Kurinij N, Dawson C R, Jones DB, Wilhelmus K R, Kaufman H E, Sugar J, Hyndiuk R A, Laibson P R, Stulting R D, Asbell P A, 1994: Herpetic Eye DiseaseStudy[J]. A controlled trial of oral acyclovir for herpes simplexstromal keratitis. Ophthalmology, 101, 1871-1882.
-
Belshe R B, Leone P A, Bernstein D I, Wald A, Levin M J, Stapleton J T, Gorfinkel I, Morrow R L, Ewell M G, Stokes-Riner A, Dubin G, Heineman T C, Schulte J M, Deal C D, Herpevac Trialfor Women, 2012: Efficacy results of a trial of a herpes simplexvaccine[J]. N Engl J Med, 366, 34-43. doi: 10.1056/NEJMoa1103151
-
Bloom J N, Palestine A G, 1988: The diagnosis of cytomegalovirus retinitis[J]. Ann Intern Med, 109, 963-969. doi: 10.7326/0003-4819-109-12-963
-
Bowen E F, Griffiths P D, Davey C C, Emery V C, Johnson MA, 1996: Lessons from the natural history of cytomegalovirus[J]. AIDS, 10, S37-S41.
-
Bradley H, Markowitz L E, Gibson T, McQuillan G M, 2014: Seroprevalence of herpes simplex virus types 1 and 2--UnitedStates, 1999-2010[J]. J Infect Dis, 209, 325-333. doi: 10.1093/infdis/jit458
-
Buxbaum S, Geers M, Gross G, Schofer H, Rabenau H F, Doerr HW, 2003: Epidemiology of herpes simplex virus types 1 and 2in Germany: what has changed?[J]. Med Microbiol Immunol, 192, 177-181. doi: 10.1007/s00430-003-0183-0
-
Caserta M T, Mock D J, Dewhurst S, 2001: Human herpesvirus 6[J]. Clin Infect Dis, 33, 829-833. doi: 10.1086/cid.2001.33.issue-6
-
Cobo L M, Foulks G N, Liesegang T, Lass J, Sutphin J E, Wilhelmus K, Jones D B, Chapman S, Segreti A C, King D H, 1986: Oral acyclovir in the treatment of acute herpes zoster ophthalmicus[J]. Ophthalmology, 93, 763-770. doi: 10.1016/S0161-6420(86)33678-9
-
Coleman J L, Shukla D, 2013: Recent advances in vaccine development for herpes simplex virus types I and II[J]. Hum VaccinImmunother, 9, 729-735.
-
Colin J, Chastel C, Kaufman H E, Kissling G E, 1987: Combination therapy for dendritic keratitis with acyclovir and vidarabine[J]. J Ocul Pharmacol, 3, 39-42. doi: 10.1089/jop.1987.3.39
-
Daibata M, Komatsu T, Taguchi H, 2000: Human herpesviruses inprimary ocular lymphoma[J]. Leuk Lymphoma, 37, 361-365.
-
Damato E G, Winnen C W, 2002: Cytomegalovirus infection: perinatal implications[J]. J Obstet Gynecol Neonatal Nurs, 31, 86-92. doi: 10.1111/j.1552-6909.2002.tb00026.x
-
Darougar S, Wishart M S, Viswalingam N D, 1985: Epidemiological and clinical features of primary herpes simplex virus ocularinfection[J]. Br J Ophthalmol, 69, 2-6. doi: 10.1136/bjo.69.1.2
-
Dartt D A, Dana R, D'Amore p, Niederkorn J. 2011. Immunology, Inflammation and Diseases of the Eye. San Diego: AcademicPress.
-
Farhatullah S, Kaza S, Athmanathan S, Garg P, Reddy S B, Sharma S, 2004: Diagnosis of herpes simplex virus-1 keratitis using Giemsa stain, immunofluorescence assay, and polymerase chain reaction assay on corneal scrapings[J]. Br J Ophthalmol, 88, 142-144. doi: 10.1136/bjo.88.1.142
-
Farooq A V, Shukla D, 2012: Herpes simplex epithelial and stromal keratitis: an epidemiologic update[J]. Surv Ophthalmol, 57, 448-462. doi: 10.1016/j.survophthal.2012.01.005
-
Farooq A V, Shah A, Shukla D, 2010: The role of herpesviruses inocular infections[J]. Virus Adaptation and Treatment, 2, 115-123.
-
Fulop T, Larbi A, Pawelec G, 2013: Human T cell aging and theimpact of persistent viral infections[J]. Front Immunol, 4, 271-.
-
Gershon A A, Gershon M D, 2010: Perspectives on vaccinesagainst varicella-zoster virus infections[J]. Curr Top Microbiol Immunol, 342, 359-372.
-
Gilden D H, Dueland A N, Devlin M E, Mahalingam R, Cohrs R, 1992: Varicella-zoster virus reactivation without rash[J]. J InfectDis, 166, S30-S34.
-
Gimenez F, Suryawanshi A, Rouse B T, 2013: Pathogenesis ofherpes stromal keratitis--a focus on corneal neovascularization[J]. Prog Retin Eye Res, 33, 1-9. doi: 10.1016/j.preteyeres.2012.07.002
-
Green L K, Pavan-Langston D, 2006: Herpes simplex ocular inflammatory disease[J]. Int Ophthalmol Clin, 46, 27-37.
-
Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau H W, Malin J P, Wutzler P, Doerr H W, 2003: Herpes zosterguideline of the German Dermatology Society (DDG)[J]. J ClinVirol, 26, 277-289.
-
Guess S, Stone D U, Chodosh J, 2007: Evidence-based treatmentof herpes simplex virus keratitis: a systematic review[J]. Ocul Surf, 5, 240-250. doi: 10.1016/S1542-0124(12)70614-6
-
Hamrah P, Sahin A, Dastjerdi M H, Shahatit B M, Bayhan HA, Dana R, Pavan-Langston D, 2012: Cellular changes of thecorneal epithelium and stroma in herpes simplex keratitis: an in vivo confocal microscopy study[J]. Ophthalmology, 119, 1791-1797. doi: 10.1016/j.ophtha.2012.03.005
-
Hennis H L, Scott A A, Apple D J, 1989: Cytomegalovirus retinitis[J]. Surv Ophthalmol, 34, 193-203. doi: 10.1016/0039-6257(89)90103-3
-
Hori J, 2008: Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation[J]. JOcul Biol Dis Infor, 1, 94-100. doi: 10.1007/s12177-008-9010-6
-
Hung S O, Patterson A, Rees P J, 1984: Pharmacokinetics of oralacyclovir (Zovirax) in the eye[J]. Br J Ophthalmol, 68, 192-195. doi: 10.1136/bjo.68.3.192
-
Hwang C W, J r., Steigleman W A, Saucedo-Sanchez E, Tuli S S, 2013: Reactivation of herpes zoster keratitis in an adult aftervaricella zoster vaccination[J]. Cornea, 32, 508-509. doi: 10.1097/ICO.0b013e318277acae
-
Kahloun R, Attia S, Jelliti B, Attia A Z, Khochtali S, Yahia S B, Zaouali S, Khairallah M, 2014: Ocular involvement and visualoutcome of herpes zoster ophthalmicus: review of 45 patientsfrom Tunisia, North Africa[J]. J Ophthalmic Inflamm Infect, 4, 25-. doi: 10.1186/s12348-014-0025-9
-
Karsten E, Watson S L, Foster L J, 2012: Diversity of microbialspecies implicated in keratitis: a review[J]. Open Ophthalmol J, 6, 110-124. doi: 10.2174/1874364101206010110
-
Kaufman H E, 1962: Clinical cure of herpes simplex keratitis by5-iodo-2-deoxyuridine[J]. Proc Soc Exp Biol Med, 109, 251-252. doi: 10.3181/00379727-109-27169
-
Keating G M, 2013: Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zosterand postherpetic neuralgia in adults aged ≥50 years[J]. Drugs, 73, 1227-1244. doi: 10.1007/s40265-013-0088-1
-
Kim S R, Khan F, Ramirez-Fort M K, Downing C, Tyring S K, 2014: Varicella zoster: an update on current treatment optionsand future perspectives[J]. Expert Opin Pharmacother, 15, 61-71. doi: 10.1517/14656566.2014.860443
-
Knickelbein J E, Hendricks R L, Charukamnoetkanok P, 2009: Management of herpes simplex virus stromal keratitis: an evidence-based review[J]. Surv Ophthalmol, 54, 226-234. doi: 10.1016/j.survophthal.2008.12.004
-
Kwong A D, Frenkel N, 1987: Herpes simplex virus-infected cellscontain a function(s) that destabilizes both host and viral mRNAs[J]. Proc Natl Acad Sci USA, 84, 1926-1930. doi: 10.1073/pnas.84.7.1926
-
Labetoulle M, Auquier P, Conrad H, Crochard A, Daniloski M, Bouee S, El Hasnaoui A, Colin J, 2005: Incidence of herpessimplex virus keratitis in France[J]. Ophthalmology, 112, 888-895. doi: 10.1016/j.ophtha.2004.11.052
-
Lairson D R, Begley C E, Reynolds T F, Wilhelmus K R, 2003: Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis[J]. Arch Ophthalmol, 121, 108-112. doi: 10.1001/archopht.121.1.108
-
Liesegang T J, 1992: Biology and molecular aspects of herpessimplex and varicella-zoster virus infections[J]. Ophthalmology, 99, 781-799. doi: 10.1016/S0161-6420(92)31921-9
-
Liesegang T J, 2008: Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity[J]. Ophthalmology, 115, S3-S12. doi: 10.1016/j.ophtha.2007.10.009
-
Liesegang T J, Melton L J, 3rd, Daly P J, Ilstrup D M. 1989. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol, 107: 1155-1159.
-
Liu S, Pavan-Langston D, Colby K A, 2012: Pediatric herpes simplex of the anterior segment: characteristics, treatment, andoutcomes[J]. Ophthalmology, 119, 2003-2008. doi: 10.1016/j.ophtha.2012.05.008
-
Matoba A Y, 1990: Ocular disease associated with Epstein-Barrvirus infection[J]. Surv Ophthalmol, 35, 145-150. doi: 10.1016/0039-6257(90)90069-8
-
Matsuo T, Itami M, 2002: Seropositivity of human herpesvirus-8in patients with uveitis[J]. Ocul Immunol Inflamm, 10, 197-199. doi: 10.1076/ocii.10.3.197.15602
-
Mechai F, Boutolleau D, Manceron V, Gasnault J, Quertainmont Y, Brosseau J P, Delfraissy J F, Labetoulle M, Goujard C, 2007: Human herpesvirus 6-associated retrobulbar optic neuritisin an HIV-infected patient: response to anti-herpesvirus therapyand long-term outcome[J]. J Med Virol, 79, 931-934. doi: 10.1002/(ISSN)1096-9071
-
Murray P R, Rosenthal K S, Pfaller M A. 2005. Human Herpesviruses Medical microbiology, 5th ed. Philadelphia: Elsevier Mosby, pp. 461-484.
-
Musch D C, Martin D F, Gordon J F, Davis M D, KuppermannB D, 1997: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant[J]. The Ganciclovir ImplantStudy Group. N Engl J Med, 337, 83-90.
-
Newman H, Gooding C, 2013: Viral ocular manifestations: a broadoverview[J]. Rev Med Virol, 23, 281-294. doi: 10.1002/rmv.v23.5
-
Nguyen L H, Knipe D M, Finberg R W, 1992: Replication-defective mutants of herpes simplex virus (HSV) induce cellularimmunity and protect against lethal HSV infection[J]. J Virol, 66, 7067-7072.
-
Nguyen Q D, Kempen J H, Bolton S G, Dunn J P, Jabs D A, 2000: Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy[J]. Am JOphthalmol, 129, 634-639. doi: 10.1016/S0002-9394(00)00356-1
-
Nilsen A, Myrmel H, 2000: Changing trends in genital herpes simplex virus infection in Bergen, Norway[J]. Acta Obstet GynecolScand, 79, 693-696.
-
Ogata N, Koike N, Yoshikawa T, Takahashi K, 2011: Human herpesvirus 6-associated uveitis with optic neuritis diagnosed bymultiplex PCR[J]. Jpn J Ophthalmol, 55, 502-505. doi: 10.1007/s10384-011-0069-4
-
Ohara P T, Chin M S, LaVail J H, 2000: The spread of herpes simplex virus type 1 from trigeminal neurons to the murine cornea:an immunoelectron microscopy study[J]. J Virol, 74, 4776-4786. doi: 10.1128/JVI.74.10.4776-4786.2000
-
Opstelten W, Zaal M J, 2005: Managing ophthalmic herpes zosterin primary care[J]. BMJ, 331, 147-151. doi: 10.1136/bmj.331.7509.147
-
Oxman, Levin, Johnson, Schmader, Straus, Gelb, Arbeit, Simberkoff, Gershon, DavisL, Weinberg, Boardman, Williams, Zhang, Peduzzi, Beisel, Morrison, Guatelli, Brooks, Kauffman, Pachucki, Neuzil, Betts, WrightP, Griffin, Brunell, Soto, Marques, Keay, Goodman, Cotton, Gnann, J, Loutit, Holodniy, Keitel, Crawford, Yeh, Lobo, Toney, Greenberg, Keller, Harbecke, Hayward, Irwin, Kyriakides, Chan, Chan, Wang, Annunziato, Silber, Shingles Prevention Study G, 2005: A vaccine toprevent herpes zoster and postherpetic neuralgia in older adults[J]. N Engl J Med, 352, 2271-2284. doi: 10.1056/NEJMoa051016
-
Palestine A G, 1988: Clinical aspects of cytomegalovirus retinitis[J]. Rev Infect Dis, 10, S515-S521.
-
Papaloukas O, Giannouli G, Papaevangelou V, 2014: Successes andchallenges in varicella vaccine[J]. Ther Adv Vaccines, 2, 39-55. doi: 10.1177/2051013613515621
-
Pepose J S, Keadle T L, Morrison L A, 2006: Ocular herpes simplex: changing epidemiology, emerging disease patterns, and thepotential of vaccine prevention and therapy[J]. Am J Ophthalmol, 141, 547-557. doi: 10.1016/j.ajo.2005.10.008
-
Centers for Disease Control and Prevention. 2012. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th ed. , second printing. Washington DC: Public Health Foundation, pp301-324.
-
Prober C G, Kirk L E, Keeney R E, 1982: Acyclovir therapy of chickenpox in immunosuppressed children--a collaborativestudy[J]. J Pediatr, 101, 622-625. doi: 10.1016/S0022-3476(82)80725-7
-
Rabenau H F, Buxbaum S, Preiser W, Weber B, Doerr H W, 2002: Seroprevalence of herpes simplex virus types 1 and type 2 in theFrankfurt am Main area, Germany[J]. Med Microbiol Immunol, 190, 153-160. doi: 10.1007/s00430-001-0102-1
-
Revere K, Davidson S L, 2013: Update on management of herpeskeratitis in children[J]. Curr Opin Ophthalmol, 24, 343-347. doi: 10.1097/ICU.0b013e32836227d8
-
Rocha G, Muzychuk M, 2010: Herpes Zoster Ophthalmicus: Morethan meets the eye[J]. Clinical & Surgical Ophthalmology, 28, 11-16.
-
Rowe A M, St Leger A J, Jeon S, Dhaliwal D K, Knickelbein J E, Hendricks R L, 2013: Herpes keratitis[J]. Prog Retin Eye Res, 32, 88-101. doi: 10.1016/j.preteyeres.2012.08.002
-
Roy F H, Fraunfelder F W, Fraunfelder F T, 2008: Roy andFraunfelder's Current Ocular Therapy[J]. Elsevier Saunders, , -.
-
Sacchetti M, Lambiase A, 2014: Diagnosis and management ofneurotrophic keratitis[J]. Clin Ophthalmol, 8, 571-579.
-
Schmader K, Gnann J W, Jr. , Watson C P. 2008. The epidemiological, clinical, and pathological rationale for the herpes zostervaccine. J Infect Dis, 197 Suppl 2: S207-S215.
-
Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D, 2009: Antiviral treatment of cytomegalovirus infection andresistant strains[J]. Expert Opin Pharmacother, 10, 191-209. doi: 10.1517/14656560802678138
-
Scoular A, Norrie J, Gillespie G, Mir N, Carman W F, 2002: Longitudinal study of genital infection by herpes simplex virus type1 in Western Scotland over 15 years[J]. BMJ, 324, 1366-1367. doi: 10.1136/bmj.324.7350.1366
-
Shaikh S, Ta C N, 2002: Evaluation and management of herpeszoster ophthalmicus[J]. Am Fam Physician, 66, 1723-1730.
-
Simberkoff, Arbeit, Johnson, Oxman, Boardman, Williams, Levin, Schmader, Gelb, Keay, Neuzil, Greenberg, Griffin, Davis, Morrison, Annunziato, Shingles Prevention Study G, 2010: Safety of herpes zoster vaccine in the shingles preventionstudy: a randomized trial[J]. Ann Intern Med, 152, 545-554. doi: 10.7326/0003-4819-152-9-201005040-00004
-
Slobod K S, Sandlund J T, Spiegel P H, Haik B, Hurwitz J L, Conley M E, Bowman L C, Benaim E, Jenkins J J, Stocks R M, Ga nY, Sixbey J W, 2000: Molecular evidence of ocular Epstein-Barrvirus infection[J]. Clin Infect Dis, 31, 184-188. doi: 10.1086/313932
-
Smith J S, Robinson N J, 2002: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review[J]. JInfect Dis, 186, S3-S28.
-
Stanberry L R, Spruance S L, Cunningham A L, Bernstein D I, Mindel A, Sacks S, Tyring S, Aoki F Y, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GlaxoSmithKline Herpes VaccineEfficacy Study G. 2002. Glycoprotein-D-adjuvant vaccine toprevent genital herpes. N Engl J Med, 347: 1652-1661.
-
Stein-Streilein J, 2008: Immune regulation and the eye[J]. Trends Immunol, 29, 548-554. doi: 10.1016/j.it.2008.08.002
-
Steiner I, Kennedy P G, Pachner A R, 2007: The neurotropic herpes viruses: herpes simplex and varicella-zoster[J]. Lancet Neurol, 6, 1015-1028. doi: 10.1016/S1474-4422(07)70267-3
-
Stewart M W, 2010: Optimal management of cytomegalovirus retinitis in patients with AIDS[J]. Clin Ophthalmol, 4, 285-299.
-
Sundmacher R. 2009. Color atlas of herpetic eye disease: a practical guide to clinical management. Berlin: Springer, pp. 51-56.
-
Sung H, Schleiss M R, 2010: Update on the current status of cytomegalovirus vaccines[J]. Expert Rev Vaccines, 9, 1303-1314. doi: 10.1586/erv.10.125
-
Suzuki T, Ohashi Y, 2008: Corneal endotheliitis[J]. Semin Ophthalmol, 23, 235-240. doi: 10.1080/08820530802111010
-
Tappuni A R, 2011: Immune reconstitution inflammatory syndrome[J]. Adv Dent Res, 23, 90-96. doi: 10.1177/0022034511399915
-
Tasman W, Jaeger E A. 2013. Duane's ophthalmology on DVDROM-2013 edition. http://80.36.73.149/almacen/medicina/oftalmologia/enciclopedias/duane/pages/v3c028a.html.
-
Toma H S, Murina A T, Areaux R G, J r., Neumann D M, Bhattacharjee P S, Foster T P, Kaufman H E, Hill J M, 2008: OcularHSV-1 latency, reactivation and recurrent disease[J]. Semin Ophthalmol, 23, 249-273. doi: 10.1080/08820530802111085
-
Tran T, Druce J D, Catton M C, Kelly H, Birch C J, 2004: Changing epidemiology of genital herpes simplex virus infection inMelbourne, Australia, between 1980 and 2003[J]. Sex Transm Infect, 80, 277-279. doi: 10.1136/sti.2004.009753
-
Tyring S K. 2006. Mucosal immunology and virology. Springer, London, pp. 179-189.
-
Tyring S K, 2007: Management of herpes zoster and postherpetic neuralgia[J]. J Am Acad Dermatol, 57, S136-S142. doi: 10.1016/j.jaad.2007.09.016
-
Varani S, Landini M P, 2011: Cytomegalovirus-induced immunopathology and its clinical consequences[J]. Herpesviridae, 2, 6-. doi: 10.1186/2042-4280-2-6
-
Varani S, Spezzacatena P, Manfredi R, Chiodo F, Mastroianni A, Ballarini P, Boschini A, Lazzarotto T, Landini M P, 2000: Theincidence of cytomegalovirus (CMV) antigenemia and CMVdisease is reduced by highly active antiretroviral therapy[J]. Eur JEpidemiol, 16, 433-437. doi: 10.1023/A:1007619323939
-
Weinberg A, Zhang J H, Oxman M N, Johnson G R, HaywardA R, Caulfield M J, Irwin M R, Clair J, Smith J G, Stanley H, Marchese R D, Harbecke R, Williams H M, Chan I S, Arbeit R D, Gershon A A, Schodel F, Morrison V A, Kauffman C A, StrausS E, Schmader K E, Davis L E, Levin M J, US Department ofVeterans Affairs (VA) Cooperative Studies Program ShinglesPrevention Study Investigators. 2009. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants ina trial of a clinically effective zoster vaccine. J Infect Dis, 200: 1068-1077.
-
Wenkel H, Rummelt V, Fleckenstein B, Naumann G O, 1998: Detection of varicella zoster virus DNA and viral antigen in humaneyes after herpes zoster ophthalmicus[J]. Ophthalmology, 105, 1323-1330. doi: 10.1016/S0161-6420(98)97042-7
-
Whitcup S M, 2000: Cytomegalovirus retinitis in the era of highlyactive antiretroviral therapy[J]. JAMA, 283, 653-657. doi: 10.1001/jama.283.5.653
-
Wilhelmus K R. 2010. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev, 12: CD002898.
-
Wilhelmus K R, Falcon M G, Jones B R, 1981: Bilateral herpetickeratitis[J]. Br J Ophthalmol, 65, 385-387. doi: 10.1136/bjo.65.6.385
-
Wong R W, Jumper J M, McDonald H R, Johnson R N, Fu A, Lujan B J, Cunningham E T Jr, 2013: Emerging concepts inthe management of acute retinal necrosis[J]. Br J Ophthalmol, 97, 545-552. doi: 10.1136/bjophthalmol-2012-301983
-
Xu F, Sternberg M R, Kottiri B J, McQuillan G M, Lee F K, Nahmias A J, Berman S M, Markowitz L E, 2006: Trends in herpessimplex virus type 1 and type 2 seroprevalence in the UnitedStates[J]. JAMA, 296, 964-973. doi: 10.1001/jama.296.8.964
-
Yawn B P, Wollan P C, St Sauver J L, Butterfield L C, 2013: Herpes zoster eye complications: rates and trends[J]. Mayo Clin Proc, 88, 562-570. doi: 10.1016/j.mayocp.2013.03.014
-
Yen M, Ausayakhun S, Chen J, Ausayakhun S, Jirawison C, Heiden D, Holland G N, Margolis T P, Keenan J D, 2014: Telemedicine diagnosis of cytomegalovirus retinitis by nonophthalmologists[J]. JAMA Ophthalmol, 132, 1052-1058. doi: 10.1001/jamaophthalmol.2014.1108